Xerava: payments to doctors
Payments that named Xerava as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.4M
- Providers
- 3,722
- Transactions
- 10,506
- Average per transaction
- $135
The per-transaction average — $135 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,722 providers the average total is $381, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Tetraphase Pharmaceuticals, Inc. | $807,623 | 56.9% |
| La Jolla Pharmaceutical Company | $604,970 | 42.6% |
| Mylan Inc. | $6,000 | 0.4% |
| Acelrx Pharmaceuticals, Inc. | $9 | 0.0% |